San Diego-based CureScience Institute, a non-profit organization dedicated to accelerating novel curative therapies, disclosed on Tuesday that Dr Boris Reznik has been appointed as an Advisory Board member.
Dr Reznik is chairman of Venvalo Group, venture value optimization firm and is a veteran of several startups.
According to CureScience Institute, Dr Reznik has a strong track record of building companies across a diverse set of technologies-based industries, primarily focused on biomedical sciences.
CEO of CureScience Institute, Dr Shashaanka Ashili, commented: "I am delighted to welcome Dr Reznik to our Advisory Board," adding "He brings a unique experience in accelerating drug and device development for life sciences companies. We at CureScienceTM look forward to benefiting from Dr Reznik's counsel as we work towards developing personalized therapeutic approaches."
Implantica's RefluxStop receives US FDA approval
Sectra to provide Education Portal to Loyalist College for medical imaging training
Aqua Medical treats second type 2 diabetes patient in IDE trial of investigational PIMA procedure
Abbott and NACHC launch nationwide Food for Health initiative
Galmed reports positive preclinical results for Aramchol in prostate cancer
Galderma receives EU approval for Restylane Shaype facial shaping injectable
Acarix's CADScor System receives UAE regulatory approval
Amsino receives Vizient contract for enteral syringes
Sisram Medical introduces Titanium Prime treatment concept in Hong Kong SAR
Proteotype unveils Alchemi platform for blood-based multi-cancer test Enlighten